Microscale radiosynthesis, preclinical imaging and dosimetry study of [18F]AMBF3-TATE: a potential PET tracer for clinical imaging of somatostatin receptors

Peptides labeled with positron-emitting isotopes are emerging as a versatile class of compounds for the development of highly specific, targeted imaging agents for diagnostic imaging via positron-emission tomography (PET) and for precision medicine via theranostic applications. Despite the success of peptides labeled with gallium-68 (for imaging) or lutetium-177 (for therapy) in the clinical management of patients with neuroendocrine tumors or prostate cancer, there are significant advantages of using fluorine-18 for imaging.

Source: Nuclear Medicine and Biology - April 20, 2018 Category: Nuclear Medicine Authors: Ksenia Lisova, Maxim Sergeev, Susan Evans-Axelsson, Andreea D. Stuparu, Seval Beykan, Jeffrey Collins, Jason Jones, Michael Lassmann, Ken Herrmann, David Perrin, Jason T. Lee, Roger Slavik, Michael van Dam Source Type: research